| Name | Title | Contact Details |
|---|
Devo Technology is a cloud-native security data platform that modernizes security operations. It serves as an alternative to traditional Security Information and Event Management (SIEM) solutions, focusing on real-time data analytics, AI-driven automation, and scalability to meet evolving cybersecurity needs. The platform integrates SIEM, Security Orchestration, Automation, and Response (SOAR), and User and Entity Behavior Analytics (UEBA) into a unified system, enabling organizations to detect threats quickly and streamline incident response. Devo offers a real-time security data platform with features like sub-second query performance, automated investigations, and global data compliance. It supports hybrid environments and scales efficiently from gigabytes to hundreds of terabytes daily. The platform is deployed on AWS and provides unlimited data ingestion and cross-border data aggregation, allowing multinational organizations to analyze data locally while maintaining global risk visibility. Devos vendor-agnostic architecture ensures full data source coverage without vendor lock-in.
Treml, Scott is a York, PA-based company in the Business Services sector.
Merchant Customs Brokers Limited is a Dorval, QC-based company in the Business Services sector.
R T R Financial Services Inc is a Staten Island, NY-based company in the Business Services sector.
InnoCare Pharma is a commercial stage biopharmaceutical company dedicated to discovering, developing, and commercializing best-in-class and/or first-in-class drugs for the treatment of cancer and autoimmune diseases. InnoCare has strong in-house innovation capabilities, holding multiple foreign and domestic patents with a rich product pipeline target liquid tumors, solid tumors, and autoimmune diseases. Our team has discovered and developed a strong pipeline. InnoCare was co-founded by Professor Shi Yigong, a world-renowned structural biologist, and Dr. Cui Jisong, an outstanding leader in the biopharmaceutical industry. We have over 1000 employees. Our core R&D staff brings rich experience from the worlds top pharmaceutical companies, such as Pfizer, GSK, Bristol-Myers Squibb, Merck, Johnson & Johnson, Bayer, etc. We are a truly global biopharmaceutical company with sites in Beijing, Nanjing, Shanghai, and Guangzhou, Hong Kong and Unites States. On March 23, 2020, InnoCare officially listed on the Hong Kong Stock Exchange (code: 9969). And on Sept. 21, 2023, InnoCare successfully got listed on STAR Board of Shanghai Stock Exchange (code: 688428). Our vision is to become a world-class biopharma leader to address the unmet medical needs globally.